Lexology February 15, 2024
It is hard to believe that we are already in February and it has been a month since the 42nd Annual JP Morgan Healthcare Conference in San Francisco wrapped. It was a packed four days in which the major players in the life sciences industry gathered to make deals, form relationships, and discuss upcoming trends for the pharmaceutical and biotechnology industry.
For those who may not have attended or for whom the week was a blur (or distant memory), below are some key takeaways in the areas of FDA regulation and corporate transactions from some of the events surrounding the conference. This includes an event held by STAT News during which the Director of the FDA Center for Biologics Evaluation...
Today's Sponsors
Today's Sponsor